MPR

Rapiblyk Receives FDA Approval for Pediatric SVT Treatment

Approval was supported by the phase 3 LANDI-PED study, which demonstrated significant heart rate reduction and conversion to normal sinus rhythm in pediatric patients.
MPR

CDC: Proportion of Extensively Drug-Resistant Shigella Isolates Increasing

Among those with XDR isolates with species information, 65.9 and 34.1 percent were Shigella sonnei and Shigella flexneri ...
MPR

Few Adults With CAP Meet Eligibility Criteria for Short-Course Antibiotics

30-day adjusted risk ratios for short- versus long-course antibiotic therapy not significant for mortality, readmission, urgent visit ...
MPR

FDA-Approved Sdamlo Provides New Option for Amlodipine Administration

The unit-dose amlodipine powder for oral solution provides a stable, preservative-free alternative for patients who struggle with traditional tablet formulations.
MPR

Capsid Assembly Modulator Pevifoscorvir Sodium Granted FDA Fast Track

Following favorable phase 1 data showing significant reductions in HBV DNA and RNA, the FDA has fast tracked pevifoscorvir sodium for chronic HBV infection.
MPR

Delgocitinib Cream Under Review for Adolescents With Chronic Hand Eczema

Delgocitinib cream was shown to be effective and well-tolerated in adolescents with chronic hand eczema in the phase 3 DELTA TEEN clinical trial.
MPR

Food Supplementation Feasible, Well Accepted for Patients Recently Hospitalized With Heart Failure

Food supplementation not associated with improvement in primary clinical outcomes, but researcher notes improvement in health-related quality of life.